Phathom Pharmaceuticals Overview
- Founded
-
2018
- Status
-
Public
- Employees
-
97
- Stock Symbol
-
PHAT
- Share Price
-
$12.00
- (As of Thursday Closing)
Phathom Pharmaceuticals General Information
Description
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Contact Information
Primary Industry
Biotechnology
Stock Exchange
NAS
Primary Office
- 100 Campus Drive
- Suite 102
- Florham Park, NJ 07932
- United States
+1 (877) 000-0000
Phathom Pharmaceuticals Timeline
Phathom Pharmaceuticals Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $12.00 | $11.72 | $6.09 - $19.95 | $499M | 41.6M | 258K | -$4.67 |
Phathom Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 321,121 | 487,879 | 758,010 | 807,112 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (158,288) | (136,615) | (125,255) | (252,035) |
| Net Income | (178,502) | (143,883) | (129,068) | (255,131) |
| Total Assets | 201,931 | 189,431 | 295,111 | 257,178 |
| Total Debt | 95,810 | 91,341 | 49,018 | 23,573 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Phathom Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Phathom Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing an
Biotechnology
Florham Park, NJ
97
As of 2022
00000
000000000
00000
000000
elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
0000000000000
Boston, MA
000
As of 0000
00000
000000 - 000
00000
000000
a commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit e
0000 000000000
Fremont, CA
000
As of 0000
00000
000000 - 000
00000
Add Comparison
Phathom Pharmaceuticals Competitors (34)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals | Formerly VC-backed | Boston, MA | 000 | 00000 | 000000 - 000 | 00000 |
| 0000000 | Formerly VC-backed | Fremont, CA | 000 | 00000 | 000000 - 000 | 00000 |
| 000000000 00000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 | 00000 |
| 000000000000000 | Formerly VC-backed | Blacksburg, VA | 0 | 00000000000 | ||
| 0000000 | Formerly PE-Backed | Boston, MA | 000 | 00000 | 000000&0 | 00000 |
Phathom Pharmaceuticals Executive Team (11)
Phathom Pharmaceuticals Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| David Socks | Self | Founder & Board Member | 000 0000 |
| Frank Karbe | Self | Board Member | 000 0000 |
| Heidi Kunz | Phathom Pharmaceuticals | Board Member | 000 0000 |
| Mark Stenhouse | Self | Board Member | 000 0000 |
| Michael Cola | Phathom Pharmaceuticals | Board Member | 000 0000 |
Phathom Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Phathom Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Phathom Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated December, 10, 2022
33.82 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 1,008
Rank
00.0
Percentile
Pharmaceuticals
Subindustry
00 of 473
Rank
00.00
Percentile
